JPH01128933A - Hyaluronidase inhibitor - Google Patents
Hyaluronidase inhibitorInfo
- Publication number
- JPH01128933A JPH01128933A JP62286187A JP28618787A JPH01128933A JP H01128933 A JPH01128933 A JP H01128933A JP 62286187 A JP62286187 A JP 62286187A JP 28618787 A JP28618787 A JP 28618787A JP H01128933 A JPH01128933 A JP H01128933A
- Authority
- JP
- Japan
- Prior art keywords
- hyaluronidase
- extract
- inhibitor
- hyaluronitase
- active ingredient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940122393 Hyaluronidase inhibitor Drugs 0.000 title abstract description 8
- 239000000284 extract Substances 0.000 claims abstract description 20
- 241000196324 Embryophyta Species 0.000 claims abstract description 6
- 239000003112 inhibitor Substances 0.000 claims abstract description 6
- 235000018185 Betula X alpestris Nutrition 0.000 claims abstract description 3
- 235000018212 Betula X uliginosa Nutrition 0.000 claims abstract description 3
- 241000736199 Paeonia Species 0.000 claims abstract description 3
- 240000007164 Salvia officinalis Species 0.000 claims abstract description 3
- 244000269722 Thea sinensis Species 0.000 claims abstract description 3
- 239000004480 active ingredient Substances 0.000 claims abstract 3
- 241000411851 herbal medicine Species 0.000 claims description 10
- 241000219108 Bryonia dioica Species 0.000 claims description 2
- 241000208690 Hamamelis Species 0.000 claims description 2
- 241000721662 Juniperus Species 0.000 claims description 2
- 241000520028 Lamium Species 0.000 claims description 2
- 235000006484 Paeonia officinalis Nutrition 0.000 claims description 2
- 235000017276 Salvia Nutrition 0.000 claims description 2
- 244000147568 Laurus nobilis Species 0.000 claims 1
- 235000017858 Laurus nobilis Nutrition 0.000 claims 1
- 235000005212 Terminalia tomentosa Nutrition 0.000 claims 1
- 108010003272 Hyaluronate lyase Proteins 0.000 abstract description 17
- 102000001974 Hyaluronidases Human genes 0.000 abstract description 17
- 229960002773 hyaluronidase Drugs 0.000 abstract description 17
- 230000000694 effects Effects 0.000 abstract description 8
- 239000003814 drug Substances 0.000 abstract description 7
- 229940079593 drug Drugs 0.000 abstract description 6
- 239000002904 solvent Substances 0.000 abstract description 5
- 206010020751 Hypersensitivity Diseases 0.000 abstract description 4
- 206010061218 Inflammation Diseases 0.000 abstract description 4
- 208000033809 Suppuration Diseases 0.000 abstract description 4
- 230000007815 allergy Effects 0.000 abstract description 4
- 230000004054 inflammatory process Effects 0.000 abstract description 4
- 208000026935 allergic disease Diseases 0.000 abstract description 2
- 230000003054 hormonal effect Effects 0.000 abstract description 2
- 239000000843 powder Substances 0.000 abstract description 2
- 241001256227 Clematis brevicaudata Species 0.000 abstract 1
- 241000208152 Geranium Species 0.000 abstract 1
- 241000208680 Hamamelis mollis Species 0.000 abstract 1
- 241000592238 Juniperus communis Species 0.000 abstract 1
- 244000303199 Lamium album Species 0.000 abstract 1
- 235000009199 Lamium album Nutrition 0.000 abstract 1
- 235000002912 Salvia officinalis Nutrition 0.000 abstract 1
- 235000006468 Thea sinensis Nutrition 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 239000001296 salvia officinalis l. Substances 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 238000000034 method Methods 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000000523 sample Substances 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 4
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 3
- BGNGWHSBYQYVRX-UHFFFAOYSA-N 4-(dimethylamino)benzaldehyde Chemical compound CN(C)C1=CC=C(C=O)C=C1 BGNGWHSBYQYVRX-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 229950001002 cianidanol Drugs 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- NZHGWWWHIYHZNX-CSKARUKUSA-N tranilast Chemical compound C1=C(OC)C(OC)=CC=C1\C=C\C(=O)NC1=CC=CC=C1C(O)=O NZHGWWWHIYHZNX-CSKARUKUSA-N 0.000 description 3
- 229960005342 tranilast Drugs 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000186427 Cutibacterium acnes Species 0.000 description 2
- 241000202807 Glycyrrhiza Species 0.000 description 2
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 2
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 2
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000000043 antiallergic agent Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229960000265 cromoglicic acid Drugs 0.000 description 2
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 229940010454 licorice Drugs 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 229940055019 propionibacterium acne Drugs 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 1
- ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- MBUVEWMHONZEQD-UHFFFAOYSA-N Azeptin Chemical compound C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 MBUVEWMHONZEQD-UHFFFAOYSA-N 0.000 description 1
- FXNFHKRTJBSTCS-UHFFFAOYSA-N Baicalein Natural products C=1C(=O)C=2C(O)=C(O)C(O)=CC=2OC=1C1=CC=CC=C1 FXNFHKRTJBSTCS-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229910052776 Thorium Inorganic materials 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 238000011861 anti-inflammatory therapy Methods 0.000 description 1
- 229960004574 azelastine Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- UDFLTIRFTXWNJO-UHFFFAOYSA-N baicalein Chemical compound O1C2=CC(=O)C(O)=C(O)C2=C(O)C=C1C1=CC=CC=C1 UDFLTIRFTXWNJO-UHFFFAOYSA-N 0.000 description 1
- 229940015301 baicalein Drugs 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- AENYAMPVQFAKHY-UHFFFAOYSA-N boric acid;potassium Chemical compound [K].OB(O)O AENYAMPVQFAKHY-UHFFFAOYSA-N 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229920002055 compound 48/80 Polymers 0.000 description 1
- RUQIISJZRVTLRM-UHFFFAOYSA-L disodium;(5,7-dihydroxy-4-oxo-2-phenylchromen-6-yl) phosphate Chemical compound [Na+].[Na+].C=1C(=O)C=2C(O)=C(OP([O-])([O-])=O)C(O)=CC=2OC=1C1=CC=CC=C1 RUQIISJZRVTLRM-UHFFFAOYSA-L 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003248 enzyme activator Substances 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229940014041 hyaluronate Drugs 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- DXDRHHKMWQZJHT-FPYGCLRLSA-N isoliquiritigenin Chemical compound C1=CC(O)=CC=C1\C=C\C(=O)C1=CC=C(O)C=C1O DXDRHHKMWQZJHT-FPYGCLRLSA-N 0.000 description 1
- JBQATDIMBVLPRB-UHFFFAOYSA-N isoliquiritigenin Natural products OC1=CC(O)=CC=C1C1OC2=CC(O)=CC=C2C(=O)C1 JBQATDIMBVLPRB-UHFFFAOYSA-N 0.000 description 1
- 235000008718 isoliquiritigenin Nutrition 0.000 description 1
- 229960004958 ketotifen Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 229940063675 spermine Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- MLCGWPUVZKTVLO-UHFFFAOYSA-N traxanox Chemical compound C=1C(C(C2=CC=CN=C2O2)=O)=C2C(Cl)=CC=1C=1N=NNN=1 MLCGWPUVZKTVLO-UHFFFAOYSA-N 0.000 description 1
- 229950011638 traxanox Drugs 0.000 description 1
- WUUHFRRPHJEEKV-UHFFFAOYSA-N tripotassium borate Chemical compound [K+].[K+].[K+].[O-]B([O-])[O-] WUUHFRRPHJEEKV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Abstract
Description
【発明の詳細な説明】
〔産業上の利用分野〕
本発明は、新規なヒアルロニターゼ阻害剤に関する。さ
らに詳しくは、化膿、炎症、■型アレルギーのヒアルロ
ニターゼに起因する疾患を予防、防止するための新規か
つ安全性の高いヒアルロニターゼ阻害剤に関する。DETAILED DESCRIPTION OF THE INVENTION [Field of Industrial Application] The present invention relates to a novel hyaluronidase inhibitor. More specifically, the present invention relates to a novel and highly safe hyaluronidase inhibitor for preventing and preventing diseases caused by hyaluronidase, such as suppuration, inflammation, and type II allergies.
従来、人体におけるヒアルロニターゼは皮膚表層に常在
するプロピオニバクテリウム アクネス（Ｐｒｏｐｉｏ
ｎｉｂａｃｔｅｒｉｕｍ ａｃｎｅｓ ）や皮膚上の一
過性の菌であるスタフィロコッカス アウレウス（Ｓｔ
ａｐｈｙｒｏｃｏｃｃｕｓ ａｕｒｅｕｓ ）などがそ
の活性を有していることが知られている（Ａｐｐｌ、
Ｍｉｃｒｏｂｉｏｌ。Conventionally, hyaluronidase in the human body is produced by Propionibacterium acnes (Propio
nibacterium acnes) and Staphylococcus aureus (St.
aphyrococcus aureus) and others are known to have this activity (Appl,
Microbiol.
ｇｙ ｑ、１４３４〜１４３６．１９６Ｂ）。スタフ
ィロコッカスアウレウスは化膿する際の原因菌として知
られているが、それが起こる際に菌がヒアルロニターゼ
を放出して皮膚組織のヒアルロニターゼを分解し増殖を
用意にしているという報告がある（Ｂｒｉｔ。gy q, 1434-1436.196B). Staphylococcus aureus is known as the causative bacterium when suppuration occurs, and there is a report that when this occurs, the bacterium releases hyaluronidase and decomposes the hyaluronidase in the skin tissue, preparing it for proliferation (Brit).
Ｊ、Ｅｘｐ、Ｐａｔｈ、２６．１２４．１９４５）。J, Exp, Path, 26.124.1945).
一方菌体由来以外の人体のヒアルロニターゼは生体内の
さまざまな組織中に、通常不活性な状態で存在するが、
Ｎａ＋、Ｋ＋、Ｃａ＋、Ｍｇ２＋などの生体内金属イオ
ンおよびスペルミンや、スペルミジンなどの生体内有機
塩基により活性化される。On the other hand, human hyaluronitase other than bacterial cell-derived hyaluronidase normally exists in an inactive state in various tissues within the body.
It is activated by in-vivo metal ions such as Na+, K+, Ca+, Mg2+, and in-vivo organic bases such as spermine and spermidine.
人体におけるヒアルロニターゼの生理学的意義は未だ不
明な点が多いが、毛細血管の透過性を光道させる起炎酵
素であること（Ｊ、Ｄｅｎｔａｌ Ｒｅ５ｔ、３３゜１
１４．１９５８）などから、炎症と関係深い酵素である
ことがいわれている（Ａｒｃｈ、 Ｐａｔｈｏｌ、、８
５，２７２゜１９６８）。またクロモグリク酸ナトリウ
ムなどのＩ型抗アレルギー剤が本酵素を阻害することな
どから、■型アレルギーにおける本酵素の関与が示唆さ
れている（Ｉｍｍｕｎｏｐｈａｒｍ、、２．１３９．１
９８０）。The physiological significance of hyaluronidase in the human body is still unclear, but it is an inflammatory enzyme that increases the permeability of capillaries (J, Dental Re5t, 33゜1
14.1958), it is said to be an enzyme closely related to inflammation (Arch, Pathol, 8).
5,272°1968). In addition, since type I antiallergic agents such as sodium cromoglycate inhibit this enzyme, the involvement of this enzyme in type II allergies has been suggested (Immunopharm, 2.139.1
980).
以上のように化膿時の悪化、炎症、Ｉ型アレルギーにヒ
アルロニターゼの関与が示唆されておりヒアルロニター
ゼを阻害すればこれらの疾患が軽減すると考えられる。As described above, it has been suggested that hyaluronidase is involved in exacerbation during suppuration, inflammation, and type I allergy, and it is thought that inhibiting hyaluronidase will alleviate these diseases.
現在までにヒアルロニターゼを阻害する抗炎症剤（イン
ドメタシン、アスピリン、メフェナム酸など）や、抗ア
レルギー剤（クロモグリク酸ナトリウム、トラニラスト
、トラキサノックス、バイカレインホスフエイト、ケト
チフェン、アゼラスチン、シアニダノール、オキサトラ
イドなど）が報告されている（Ｐｈｙｓｉｏｌ、 Ｒｅ
ｖ、 ２７．４３６．１９４７゜炎症と抗炎症療法、医
歯薬出版、７．４１１．１９８２）。To date, there are anti-inflammatory drugs that inhibit hyaluronidase (indomethacin, aspirin, mefenamic acid, etc.) and anti-allergic drugs (sodium cromoglycate, tranilast, traxanox, baicalein phosphate, ketotifen, azelastine, cyanidanol, oxatride, etc.). has been reported (Physiol, Re
v, 27.436.1947゜Inflammation and anti-inflammatory therapy, Ishiyaku Publishing, 7.411.1982).
生薬については、甘草成分のりクイリチゲニンやイソリ
クイリチゲニン、黄募成分のパイカリン、バイカレイン
などに強いヒアルロニターゼ阻害が認められている。Regarding herbal medicines, strong hyaluronitase inhibition has been observed in licorice ingredients such as Noriquiritigenin and Isoliquiritigenin, as well as picalin and baicalein, which are licorice ingredients.
、しかしこれらの物質はほかの配合成分との関係からヒ
アルロニターゼ阻害効果を発揮できなかったり、局所適
用における安全性有効性の点で必ずしも満足しえない。However, these substances may not be able to exhibit hyaluronidase inhibitory effects due to their relationship with other ingredients, or may not always be satisfactory in terms of safety and effectiveness when applied topically.
本発明は、現存するヒアルロニターゼ阻害剤の満足でき
ない点を考慮し、安全性が高く真にヒアルロニターゼ阻
害効果に優れた薬剤を得るべく鋭意研究を重ねた結果、
現在地の用途に使用されている数多くの生薬抽出エキス
にヒアルロニターゼ■害作用があるという全く新規な事
実を見出しこの知見にもとづいて本発明を完成するに至
った。The present invention was developed in consideration of the unsatisfactory points of existing hyaluronitase inhibitors, and as a result of intensive research to obtain a drug that is highly safe and truly has an excellent hyaluronitase inhibitory effect.
We have discovered a completely new fact that many extracts of herbal medicines currently in use have harmful effects on hyaluronitase, and based on this knowledge we have completed the present invention.
すなわち本発明は、シャクヤク、オオレン、オオバク、
ボタンピ、ゲンノショウコ、茶、クジン、シボタンツル
、オドリコソウ、サルビア、西洋ネズ、ハマメリスおよ
びバーチからなる群の１種または２種以上から選ばれる
生薬、または上記群の１種または２種以上から選ばれた
植物の溶媒抽出エキスを有効成分とするヒアルロニター
ゼ阻害剤を提供するものである。That is, the present invention can be applied to peonies, orensis, orientalis,
A herbal medicine selected from one or more of the group consisting of Botanical herb, blackberry, tea, Japanese vine, white vine, dead nettle, salvia, juniper, Hamamelis, and birch, or a plant selected from one or more of the above group. The present invention provides a hyaluronidase inhibitor containing a solvent extracted extract of .
以下本発明について詳しく説明する。The present invention will be explained in detail below.
本発明における生薬とは植物体を乾燥し、粉砕したもの
であり、溶媒抽出エキスとは、特に明記しない限り次の
方法によって得られる上記植物またはその生薬抽出液、
その希釈液、その濃縮エキスあるいはその乾燥床を意味
するものとする。In the present invention, the herbal medicine is a dried and crushed plant, and the solvent-extracted extract means the above-mentioned plant or herbal medicine extract obtained by the following method, unless otherwise specified.
It shall mean its diluted solution, its concentrated extract or its drying bed.
溶媒抽出エキスは、上記植物または生薬乾燥床を、水も
しくは有機溶媒（石油エーテル、シクロヘキサン、四塩
化炭素、トルエン、ベンゼン、ジクロルメタン、クロロ
ホルム、エーテル、酢酸エチル、ブタノール、アセトン
、ｎ−プロパツール、エタノール、メタノール、ピリジ
ン、ポリエチレングリコール、プロピレングリコール）
あるいはそれらを一定の比率で混合した溶媒、たとえば
、水性アルコールを用い、通常３℃〜７０℃で抽出処理
して得られる。以上の生薬、溶媒抽出は、そのまま、ま
たは希釈あるいは濃縮し、もしくは凍結乾燥した後、粉
末またはペースト状に調製し所望により適宜製剤化しヒ
アルロニターゼ阻害剤として用いることができる。Solvent extraction extracts are obtained by extracting the above plants or herbal medicines from a dry bed using water or organic solvents (petroleum ether, cyclohexane, carbon tetrachloride, toluene, benzene, dichloromethane, chloroform, ether, ethyl acetate, butanol, acetone, n-propanol, ethanol). , methanol, pyridine, polyethylene glycol, propylene glycol)
Alternatively, it can be obtained by extraction using a solvent in which they are mixed at a certain ratio, such as aqueous alcohol, usually at 3°C to 70°C. The above herbal medicines and solvent extraction can be used as hyaluronidase inhibitors as they are, or after being diluted, concentrated, or lyophilized, prepared into a powder or paste form, and formulated into an appropriate formulation as desired.
〔発明の効果〕ｌ１−ｔＡ・“〔費穂ｏｔり本発明のヒ
アルロニターゼ阻害剤は以下に説明する実施例から分か
るように、ヒアルロニターゼを強力かつ有効に抑制する
。さらに皮膚に対する刺激やホルモン様副作用を全く与
えないので皮膚に対して非常に安全である。[Effects of the Invention] The hyaluronidase inhibitor of the present invention strongly and effectively inhibits hyaluronidase, as can be seen from the examples described below.Furthermore, it does not cause irritation to the skin or hormone-like side effects. It is extremely safe for the skin as it does not give any irritation to the skin.
（実施例１）
（１） ヒアルロニターゼの調製
ヒアルロニターゼ（牛畢丸由来シグマ社製）を最終濃度
が３４０ ＮＦｕｎｉｔ ／ ｍｌとなるように０．１
Ｍ酢酸緩衝液ＰＨ３，５調製した。(Example 1) (1) Preparation of hyaluronitase Hyaluronitase (derived from Ushibimaru, manufactured by Sigma) was added to a final concentration of 0.1 to give a final concentration of 340 NFunit/ml.
M acetate buffer PH3,5 was prepared.
（２）溶媒抽出エキス試料の調製
乾燥し粉砕した生薬１〜１０ｇに１０倍量の水、メタノ
ールまたはこれらの混液を加え、振盪抽出するかまたは
、加熱還流下に抽出した後上漬と沈渣に分離した。上清
を減圧下に濃縮乾固して生薬抽出エキスを得、必要に応
じてこれを水またはメタノールで希釈して生薬抽出エキ
ス試料とした。(2) Preparation of solvent-extracted extract sample Add 10 times the amount of water, methanol, or a mixture thereof to 1 to 10 g of dried and ground herbal medicine, and extract with shaking or extract under heating and reflux, and then soak in the supernatant and precipitate. separated. The supernatant was concentrated to dryness under reduced pressure to obtain a crude drug extract, which was diluted with water or methanol as necessary to prepare a crude drug extract sample.
（３） ヒアルロニターゼ活性測定法ヒアルロニター
ゼ活性測定は、モルガンーエルソン（Ｍｏｒｇａｎ−Ｅ
ｌｓｏｎ）法を応用する方法に従って行った（ｉｂｉｄ
、、２４２，４３７．１９６７ ）。(3) Hyaluronitase activity measurement method Hyaluronitase activity measurement is carried out by Morgan-Ellson (Morgan-E
It was carried out according to the method of applying the method (ibid
, 242, 437.1967).
′酵素の緩衝溶液０．１ｍｌに、酵素の活性化剤の緩衝
液０．２ｍｌずつを加え、３７℃で２０分間放置し酵素
を活性化した。次に（２）溶媒抽出エキス試料の調製で
調製した溶媒抽出エキス試料の緩衝液あるいは炭酸ナト
リウム中和水溶液０．２ｍｌずつを加え、３７℃で２０
分間放置した。対象として用いる酵素溶液には、試料の
緩衝溶液あるいは炭酸ナトリウム中和水溶液０．２ｍｌ
のかわりに、緩衝液あるいは水０．２ｍｌずつを加えた
。その後ヒアルロン酸カリウム緩衝液０．５ｍｌを加え
、３７℃で４０分間反応させた。'To 0.1 ml of the enzyme buffer solution, 0.2 ml of the enzyme activator buffer was added, and the mixture was left at 37° C. for 20 minutes to activate the enzyme. Next, add 0.2 ml each of the buffer solution or sodium carbonate neutralized aqueous solution of the solvent extracted extract sample prepared in (2) Preparation of the solvent extracted extract sample, and
Leave it for a minute. The enzyme solution used as a target contains 0.2 ml of the sample buffer solution or sodium carbonate neutralized aqueous solution.
Instead, 0.2 ml each of buffer solution or water was added. Thereafter, 0.5 ml of potassium hyaluronate buffer was added and reacted at 37°C for 40 minutes.
０．４Ｎ水酸化ナトリウム０．２ｎ＋１を加えて反応を
停止した後、モルガンーエルフン法により発色させ５８
５ｍｍにおける吸光度を測定した。After stopping the reaction by adding 0.2n+1 of 0.4N sodium hydroxide, color was developed by the Morgan-Elfn method.
Absorbance at 5 mm was measured.
Ｏモルガンーエルフン法
各反応液にホウ酸カリ溶液を加え、水溶中で３分間加熱
した後、流水中で冷却し、Ｐ−ジメチルアミノベンズア
ルデヒド試薬６．０ＬＩｌｌを加えた。O. Morgan-Elfn method Potassium borate solution was added to each reaction solution, heated in water for 3 minutes, cooled in running water, and 6.0 LIll of P-dimethylaminobenzaldehyde reagent was added.
直ちに振盪した後、３７℃で２０分間発色させ５８５ｍ
ｍにおける吸光度を測定した。After shaking immediately, the color was developed for 20 minutes at 37°C.
The absorbance at m was measured.
（ホウ酸カリ溶液： ０，８Ｍホウ酸水溶液１００＋
ａｌに水酸化カリウム２．２４ｇを加え溶解した。(Potassium boric acid solution: 0.8M boric acid aqueous solution 100+
2.24 g of potassium hydroxide was added to al and dissolved.
Ｐ−ジメチルアミノベンズアルデヒド：Ｐ−ジメチルア
ミノベンズアルデヒド１０ｇを酢酸８７ 、５ｍ ｌお
よびＩＯＮ塩酸１２．５ｍｌに溶解した。本試薬は通常
冷蔵保存しておき、用時酢酸で１０倍希釈した。P-dimethylaminobenzaldehyde: 10 g of P-dimethylaminobenzaldehyde was dissolved in 5 ml of acetic acid 87 and 12.5 ml of ION hydrochloric acid. This reagent is usually stored refrigerated and diluted 10 times with acetic acid before use.
阻害率は、式（１）により算出した。The inhibition rate was calculated using formula (1).
ｃｏｍｐｏｕｎｄ４８／ ８０ （シグマ社製）の最終
濃度が、それぞれ２．５ｎ＋Ｍ、０．１５Ｍおよび０．
１ｍｇ／ｍｌとなるように調製した緩衝溶液を用いた。The final concentrations of compound 48/80 (manufactured by Sigma) were 2.5n+M, 0.15M and 0.5n+M, respectively.
A buffer solution prepared to have a concentration of 1 mg/ml was used.
その結果を表−１に示した。The results are shown in Table-1.
（比較例１）
（１） ヒアルロニターゼの調製
実施例１の（１）ヒアルロニターゼの調製と同様に調製
した。(Comparative Example 1) (1) Preparation of hyaluronitase It was prepared in the same manner as (1) Preparation of hyaluronitase in Example 1.
（２） ヒアルロニターゼ阻害剤の調製ヒアルロニタ
ーゼ阻害効果のある薬剤として知られているトラニラス
ト、クロルモノグリフ酸ナトリウム、シアニダノールの
試料を調製した。(2) Preparation of hyaluronitase inhibitors Samples of tranilast, sodium chlormonoglyphate, and cyanidanol, which are known as drugs having a hyaluronitase inhibitory effect, were prepared.
（３） ヒアルロニターゼ活性の測定法実施例１ 、
（３）ヒアルロニターゼ活性の測定法に準じて操作した
。(3) Example 1 of the method for measuring hyaluronidase activity,
(3) The procedure was performed according to the method for measuring hyaluronidase activity.
その結果を表−１に示した。The results are shown in Table-1.
表−１各種生薬抽出エキスのヒアルロニターゼ阻害効果
とヒアルロニターゼ表−１から明らかなように本発明に
係るヒアルロニターゼ阻害剤は、生薬抽出エキス試料が
反応系中に０．００１〜０．１％存在する場合、２０％
〜８５％のヒアルロニターゼ阻害作用を示すことがわか
る。Table 1: Hyaluronitase inhibitory effect of various herbal medicine extracts and hyaluronidase As is clear from Table 1, the hyaluronidase inhibitor according to the present invention is effective when the crude medicine extract sample is present in the reaction system at 0.001 to 0.1%. ,20%
It can be seen that it exhibits ~85% hyaluronidase inhibitory effect.
さらにヒアルロニターゼ阻害剤として知られているトラ
ニラスト、クロルモノグリフ酸ナトリウム、シアニダノ
ールは、反応系中に０．１％存在しても、クロルモノグ
リフ酸トリウム以外は５０％以下のヒアルロニターゼ阻
害作用しかないことがわかった。Furthermore, even if tranilast, sodium chlormonoglyphate, and cyanidanol, which are known as hyaluronitase inhibitors, are present in the reaction system at 0.1%, they have a hyaluronitase inhibitory effect of less than 50%, except for thorium chlormonoglynate. I understand.
特許出願人 株式会社 資生堂Patent applicant: Shiseido Co., Ltd.
Claims (1)
ョウコ、茶、クジン、シボタンツル、オドリコソウ、サ
ルビア、西洋ネズ、ハマメリス、およびバーチからなる
群の１種または２種以上から選ばれる生薬、または上記
群の一種または２種以上から選ばれた植物の溶媒抽出エ
キスを有効成分とするヒアルロニターゼ阻害剤Herbal medicines selected from one or more of the group consisting of peonies, oriental laurel, giant tabara, botanpi, genus shoko, tea, kujin, white vine, dead nettle, salvia, juniper, hamamelis, and birch, or one or two of the above groups. A hyaluronitase inhibitor whose active ingredient is a solvent-extracted extract of a plant selected from the above.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP62286187A JPH01128933A (en) | 1987-11-12 | 1987-11-12 | Hyaluronidase inhibitor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP62286187A JPH01128933A (en) | 1987-11-12 | 1987-11-12 | Hyaluronidase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH01128933A true JPH01128933A (en) | 1989-05-22 |
Family
ID=17701074
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP62286187A Pending JPH01128933A (en) | 1987-11-12 | 1987-11-12 | Hyaluronidase inhibitor |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH01128933A (en) |
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0211520A (en) * | 1988-06-29 | 1990-01-16 | Momotani Jiyuntenkan:Kk | Hyaluronidase inactivation agent |
| JPH0377829A (en) * | 1989-08-18 | 1991-04-03 | Kiyuukiyuu Yakuhin Kogyo Kk | Crude drug plaster preparation |
| JPH0616530A (en) * | 1992-07-03 | 1994-01-25 | Mikimoto Pharmaceut Co Ltd | Cosmetic |
| JPH0987189A (en) * | 1995-09-19 | 1997-03-31 | Ichimaru Pharcos Co Ltd | Antiallergic agent containing isodon japonicus hara, paeonia suffruticosa andrews, perilla frutescens britton var. acuta kudo, and/or arunica montana linne |
| JP2000297044A (en) * | 1999-04-13 | 2000-10-24 | Sunstar Inc | Transdermal patch for external use for skin |
| US6193977B1 (en) | 1999-03-18 | 2001-02-27 | Medvill Co., Ltd. | Pharmaceutical composition comprising an aqueous extract of a mixture of anemarrhena rhizoma and phellodedron bark for analgesic and anti-inflammation |
| JP2003012489A (en) * | 2001-07-02 | 2003-01-15 | Naris Cosmetics Co Ltd | Hyaluronidase activity inhibitor and moisture-retaining cosmetic |
| JP2003238432A (en) * | 2002-02-15 | 2003-08-27 | Fancl Corp | Hyaluronic acid acuumulation-accelerating agent |
| US6630176B2 (en) * | 2000-03-07 | 2003-10-07 | Mount Sinai School Of Medicine Of New York University | Herbal remedies for treating allergies and asthma |
| JP2004002433A (en) * | 2003-06-02 | 2004-01-08 | Pola Chem Ind Inc | Skin external preparation for alpha-msh suppression |
| KR100720670B1 (en) * | 2006-02-22 | 2007-05-21 | 경희대학교 산학협력단 | The composition comprising extracts of phellodendri cortex and coptis chinensis for treatment of type iv allergy and an inflammation |
| KR100720671B1 (en) * | 2006-02-23 | 2007-05-21 | 경희대학교 산학협력단 | The composition comprising extracts of gentiana scabra, citrus unshiu marcor and coptis chinensis for treatment of type iv allergy and an inflammation |
| JP2009067804A (en) * | 2008-10-30 | 2009-04-02 | Pola Chem Ind Inc | SKIN EXTERNAL PREPARATION FOR WHITENING RELATING TO alpha-MSH |
| JP2010260808A (en) * | 2009-05-01 | 2010-11-18 | Ikeda Mohando:Kk | Oral medicinal composition for improving skin condition |
| US8101211B2 (en) | 2000-12-15 | 2012-01-24 | Kabushiki Kaisha Yakult Honsha | Compositions for retarding skin aging |
| JP2023145053A (en) * | 2022-03-28 | 2023-10-11 | 株式会社ナリス化粧品 | Hyaluronidase inhibitor |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS55127309A (en) * | 1979-03-23 | 1980-10-02 | Kishiyouhin Kagaku Kaihou Kenkyusho:Kk | Cosmetic |
| JPS5838209A (en) * | 1981-08-29 | 1983-03-05 | Sunstar Inc | Tannin-containing composition for skin for external application |
| JPS5973509A (en) * | 1982-10-18 | 1984-04-25 | Osaka Chem Lab | Cosmetic composition containing ogon |
| JPS59216810A (en) * | 1983-05-24 | 1984-12-06 | Osaka Chem Lab | Cosmetic composition containing catechin compound |
| JPS60146829A (en) * | 1984-01-05 | 1985-08-02 | Rooto Seiyaku Kk | Testosterone 5alpha-reductase inhibitor |
| JPS6150922A (en) * | 1984-08-20 | 1986-03-13 | Ichimaru Fuarukosu Kk | External drug for skin containing extracted component of "oubaku" |
| JPS62207224A (en) * | 1986-03-08 | 1987-09-11 | Nippon Haipotsukusu:Kk | Side effect reducing preparation for antitumor agent |
| JPS6450877A (en) * | 1987-08-20 | 1989-02-27 | Ichimaru Pharcos Inc | Oxygen radical catching and removing agent |
-
1987
- 1987-11-12 JP JP62286187A patent/JPH01128933A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS55127309A (en) * | 1979-03-23 | 1980-10-02 | Kishiyouhin Kagaku Kaihou Kenkyusho:Kk | Cosmetic |
| JPS5838209A (en) * | 1981-08-29 | 1983-03-05 | Sunstar Inc | Tannin-containing composition for skin for external application |
| JPS5973509A (en) * | 1982-10-18 | 1984-04-25 | Osaka Chem Lab | Cosmetic composition containing ogon |
| JPS59216810A (en) * | 1983-05-24 | 1984-12-06 | Osaka Chem Lab | Cosmetic composition containing catechin compound |
| JPS60146829A (en) * | 1984-01-05 | 1985-08-02 | Rooto Seiyaku Kk | Testosterone 5alpha-reductase inhibitor |
| JPS6150922A (en) * | 1984-08-20 | 1986-03-13 | Ichimaru Fuarukosu Kk | External drug for skin containing extracted component of "oubaku" |
| JPS62207224A (en) * | 1986-03-08 | 1987-09-11 | Nippon Haipotsukusu:Kk | Side effect reducing preparation for antitumor agent |
| JPS6450877A (en) * | 1987-08-20 | 1989-02-27 | Ichimaru Pharcos Inc | Oxygen radical catching and removing agent |
Cited By (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0211520A (en) * | 1988-06-29 | 1990-01-16 | Momotani Jiyuntenkan:Kk | Hyaluronidase inactivation agent |
| JPH0377829A (en) * | 1989-08-18 | 1991-04-03 | Kiyuukiyuu Yakuhin Kogyo Kk | Crude drug plaster preparation |
| JPH0616530A (en) * | 1992-07-03 | 1994-01-25 | Mikimoto Pharmaceut Co Ltd | Cosmetic |
| JPH0987189A (en) * | 1995-09-19 | 1997-03-31 | Ichimaru Pharcos Co Ltd | Antiallergic agent containing isodon japonicus hara, paeonia suffruticosa andrews, perilla frutescens britton var. acuta kudo, and/or arunica montana linne |
| US6193977B1 (en) | 1999-03-18 | 2001-02-27 | Medvill Co., Ltd. | Pharmaceutical composition comprising an aqueous extract of a mixture of anemarrhena rhizoma and phellodedron bark for analgesic and anti-inflammation |
| JP2000297044A (en) * | 1999-04-13 | 2000-10-24 | Sunstar Inc | Transdermal patch for external use for skin |
| US6630176B2 (en) * | 2000-03-07 | 2003-10-07 | Mount Sinai School Of Medicine Of New York University | Herbal remedies for treating allergies and asthma |
| US8101211B2 (en) | 2000-12-15 | 2012-01-24 | Kabushiki Kaisha Yakult Honsha | Compositions for retarding skin aging |
| JP2003012489A (en) * | 2001-07-02 | 2003-01-15 | Naris Cosmetics Co Ltd | Hyaluronidase activity inhibitor and moisture-retaining cosmetic |
| JP2003238432A (en) * | 2002-02-15 | 2003-08-27 | Fancl Corp | Hyaluronic acid acuumulation-accelerating agent |
| JP4542300B2 (en) * | 2002-02-15 | 2010-09-08 | 株式会社ファンケル | Hyaluronic acid accumulation promoter |
| JP2004002433A (en) * | 2003-06-02 | 2004-01-08 | Pola Chem Ind Inc | Skin external preparation for alpha-msh suppression |
| JP4574959B2 (en) * | 2003-06-02 | 2010-11-04 | ポーラ化成工業株式会社 | External skin preparation for suppressing α-MSH |
| KR100720670B1 (en) * | 2006-02-22 | 2007-05-21 | 경희대학교 산학협력단 | The composition comprising extracts of phellodendri cortex and coptis chinensis for treatment of type iv allergy and an inflammation |
| KR100720671B1 (en) * | 2006-02-23 | 2007-05-21 | 경희대학교 산학협력단 | The composition comprising extracts of gentiana scabra, citrus unshiu marcor and coptis chinensis for treatment of type iv allergy and an inflammation |
| JP2009067804A (en) * | 2008-10-30 | 2009-04-02 | Pola Chem Ind Inc | SKIN EXTERNAL PREPARATION FOR WHITENING RELATING TO alpha-MSH |
| JP2010260808A (en) * | 2009-05-01 | 2010-11-18 | Ikeda Mohando:Kk | Oral medicinal composition for improving skin condition |
| JP2023145053A (en) * | 2022-03-28 | 2023-10-11 | 株式会社ナリス化粧品 | Hyaluronidase inhibitor |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH01128933A (en) | Hyaluronidase inhibitor | |
| US9138451B2 (en) | Plant extract hydrolysates and antibacterial product containing the same | |
| US10967030B2 (en) | Traditional Chinese medicine composition for treating psoriasis and method for preparing the same | |
| CN102293724B (en) | Cosmetic composition containing Chinese herbal compounds | |
| HU229230B1 (en) | Medical composition for the treatment of herpes simplex virus and other infectious diseases | |
| WO2008140200A1 (en) | External compositions for the skin | |
| JPS60156618A (en) | Cosmetic or medicinal composition based on plant extract | |
| CN102579525A (en) | Ilex rotunda thunb extract and preparation method and application thereof | |
| CN102258637A (en) | Callicarpa nudiflora extract, and preparation method and application thereof | |
| CN102258746B (en) | Ointment for treating surface of burns and scalds | |
| Kamburoğlu et al. | Analgesic effect of Anatolian propolis in mice | |
| Manosroi et al. | Potent hypoglycemic effect of Nigerian anti-diabetic medicinal plants | |
| Cheesman et al. | An assessment of the growth inhibition profiles of Hamamelis virginiana L. extracts against Streptococcus and Staphylococcus spp. | |
| Nand et al. | In vitro and in vivo assessment of polyherbal topical gel formulation for the treatment of acne vulgaris | |
| CN101040957B (en) | Medicine for treating skin diseases such as eczema and dermatitis and the method for preparing the same | |
| Aina et al. | In vitro investigations into the antioxidant and anti-Inflammatory potentials of the fractions and ethanolic extract of Cyclosorus afer (christ.) Ching, stalks | |
| JPH0687731A (en) | Cosmetic | |
| JP2599152B2 (en) | Agent for prevention and treatment of pasturellosis in pigs | |
| JPH01128934A (en) | Protease inhibitor | |
| JP3292869B2 (en) | Hyaluronidase inhibitor | |
| JPH01172340A (en) | Preventive and remedy for staphylococcal disease of chicken | |
| CN111388523A (en) | Preparation for treating acne and preparation method thereof | |
| JP3487619B2 (en) | 5α-reductase inhibitor | |
| CN111358851A (en) | Gel for treating pet skin diseases and preparation method thereof | |
| Soni et al. | Formulation, development and evaluation of polyherbal gel for topical infection |